The Therapeutics Of ELEOTIN In The Treatment Of Non-insulin Dependent Diabetes Mellitus (NIDDM)

A report to inform diabetics and health care professionals of recent studies showing the therapeutic values of a herbal product developed in Canada for the treatment of non-insulin dependent diabetes mellitus (NIDDM). This report brings evidence to the diabetic and the professional health care practitioner that there is an effective non-toxic treatment for NIDDM, without side effects, that often results in a cure for the patient.

Published By:
U.S. Research Reports, Inc.

Post Office Box 7802
Metairie, LA. 70010
Introduction This report is intended to inform diabetics and healthcare professionals of a recent study showing the therapeutic values of a herbal product developed in Canada for the treatment of non-insulin dependent diabetes mellitus (NIDDM).In addition to the most advanced drugs used in the treatment of NIDDM, there are reported to be more than 2,000 herbs that have the ability to lower sugar levels in the blood. However, many of these are toxic and have side effects and none of these are reported to have the effectiveness or cure rates achieved with the ELEOTIN herbal treatment studied in this report. In addition, as shown in this report, the current treatment of NIDDM with drugs has both toxicity and adverse side effects.As this report points out, NIDDM, unlike Type I diabetes where there is no insulin production by the pancreatic ß -cells, is not always caused by low levels of plasma insulin. Many patients with NIDDM have normal to high levels of insulin in the blood. In these cases, diabetes is not caused by a shortage of insulin, but maybe the results of defects in the molecular machinery that mediates the action of insulin on its target cells. In other words, NIDDM is not always caused by the destruction of ß-cells in the pancreas but by other mechanisms, such as insulin resistance, related to down-regulation of insulin receptors, defects in insulin secretion from the pancreatic ß -cells and other changes to the glucose transporter system. In these regards, one of the most important benefits of the ELEOTIN therapy is its effectiveness in those diabetic cases involving insulin resistance, which is the condition described as follows:The pancreas usually continues to produce some insulin in people with NIDDM. However, the insulin fails to limit the level of glucose in the blood. When insulin is present in the blood but the blood fails to maintain a normal level of glucose, the condition is called “insulin resistance.” Insulin resistance is an important factor in NIDDM. A defect in the insulin receptors on the surface of cells may cause insulin resistance. In some cases there may not be a sufficient number of receptors on the cells for insulin or defects in the receptors may prevent insulin from binding to the cells. Insulin resistance may also involve the step after insulin binds with the insulin receptor. For example, insulin may bind to the receptor but the next step that should take place inside the cell does not occur and the cells do not perform their glucose-controlling task.More often than not, the diabetic medicines of today become ineffective over time and the treated patient’s health condition seriously deteriorates and often results in blindness, heart disease, amputations and death. Most current options of treatment provide symptomatic or temporary treatment rather than long-term permanent solutions. ELEOTIN is a candidate for a long-term solution to diabetes and its complications.This report brings evidence to the diabetic and the professional health care practitioner that there is an effective treatment for NIDDM and it often results in a cure for the patient. Extensive research on over 800 herbs, and combinations thereof, by some of the world’s most prominent physicians in the field of diabetes has produced this non-toxic therapy. It is a shining star in the darkness that has surrounded diabetes for centuries.Reports of successful treatment and cures of NIDDM are being received daily as this report is being readied for publication and therefore supplemental reports and clinical studies will be published on this subject in the future.The information in this report has not been reviewed by any regulatory body such as the FDA and is not intended to replace instructions by physicians.U.S. RESEARCH REPORTS, INC.

ELEOTIN: Promising New Treatment for Diabetes 1
Diabetes mellitus (hereinafter, diabetes) is a growing public health problem in both developed and developing countries. A recent World Health Organisation report estimated that more than 100 million people worldwide will suffer from diabetes by the end of this century.

Over 16 million people in the United States have diabetes, a serious life-long disorder. Almost half of these people do not know they have diabetes and are not under medical care. Each year, 500,000 to 700,000 people are diagnosed with diabetes in the United States.